[7] This pragmatic, randomized, double-blind, placebo-controlled, event-driven trial found that patients randomized to EQW had a numerically lower incidence of major adverse cardiovascular events, and a nominally significant reduction in all-cause mortality.
← all excerpts
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.
1
—
—